Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only limited portions of the dosing claims partially align with the provided label excerpt (renal-function–dependent regimens in Table 1). Most other claims (pricing, availability, patents, coupons/assistance, generic equivalence/details, mechanism, and HSV/VZV alternatives) are not supported by the supplied labeling text and are therefore unsupported by the label.
Category Scores
Accurate Statements
For shingles, a typical dosage of valacyclovir is 1 g taken three times daily for seven days.
Partially supported by Dosage and Administration (2.4), Table 1 showing herpes zoster dosing as 1 gram every 8 hours for normal renal function; however the 7-day duration is not confirmed by the provided excerpt.
A 1 g dose of valacyclovir is often prescribed for conditions like shingles or genital herpes outbreaks.
Partially supported by Dosage and Administration (2.4), Table 1 listing 1 gram regimens for herpes zoster (frequency depends on renal function) and genital herpes (e.g., initial episode regimen). The claim is broadly phrased and does not match label specifics.
Unsupported Statements
Without insurance, a 30-day supply of brand-name valacyclovir (Valtrex) may cost upwards of $400.
Pricing/cost amounts are not stated in the supplied prescribing information.
Generic versions of valacyclovir are widely available and can reduce cost, potentially to $50–$100 for a 30-day supply.
No availability or cost figures are provided in the supplied label text.
Valacyclovir price varies depending on the specific retail pharmacy and the number of tablets in the prescription.
No retail/pricing/quantity-based pricing guidance is included in the supplied label.
The introduction of generic alternatives is a major driver of valacyclovir cost reduction.
No policy/market drivers of cost reduction are discussed in the supplied label.
Patent expiries allow other manufacturers to produce and sell valacyclovir versions that are typically much cheaper than the original branded product.
Patent timing/cost-comparison assertions are not present in the supplied label.
Insurance plans can result in substantially lower co-pays for generic medications.
No insurance/co-pay statements are included in the supplied label.
Pharmacy pricing strategies and discounts contribute to price variations for valacyclovir.
No discount/strategy statements are included in the supplied label.
Comparing prices across different pharmacies is recommended to find the most affordable valacyclovir.
The supplied label does not recommend comparing retail prices.
Online pharmacies and discount prescription programs can offer lower prices than traditional brick-and-mortar stores.
No statements about online pharmacies/discount programs exist in the supplied label.
Asking a doctor about generic options can lead to significant savings on valacyclovir.
The supplied label does not discuss savings from generic option discussions.
Websites like DrugPatentWatch.com provide information on drug patents, which can indicate when generic versions might become available, influencing future pricing.
No external website or patent-watch guidance is included in the supplied label.
Discount programs and coupons are frequently available for valacyclovir, particularly for the brand-name version.
No coupon/discount program statements are included in the supplied label.
Pharmaceutical manufacturers often offer patient assistance programs for valacyclovir.
No patient assistance program statements are included in the supplied label.
Online coupon aggregators provide discounts that can be applied at most pharmacies.
No information about coupon aggregators is included in the supplied label.
Generic valacyclovir is already considerably less expensive, but coupons or programs can still offer additional savings.
No cost/savings or coupon/program statements are included in the supplied label.
Patent exclusivity for valacyclovir (Valtrex) has expired in major markets.
No patent exclusivity status is described in the supplied label excerpt.
In the United States, generic valacyclovir became available around 2017.
No generic launch date is provided in the supplied label excerpt.
FDA requires generic drugs to meet the same standards for safety, efficacy, and quality as their brand-name counterparts.
No regulatory/general-generic standards discussion appears in the supplied label excerpt.
Generic valacyclovir is bioequivalent to brand-name valacyclovir (Valtrex).
No bioequivalence statements are included in the supplied label excerpt.
Generic valacyclovir contains the same active ingredient, at the same strength, and is administered in the same way as brand-name valacyclovir (Valtrex).
No generic composition/administration equivalence statements are included in the supplied label excerpt.
The primary difference between generic and brand-name valacyclovir is usually inactive ingredients such as fillers, dyes, and binders.
No generic vs brand ingredient-difference statement is included in the supplied label excerpt.
Valacyclovir works by inhibiting viral DNA replication.
The provided Mechanism of Action excerpt states it is an antiviral active against α-herpes viruses, but does not explicitly support the specific mechanism wording 'inhibiting viral DNA replication.'
Acyclovir and famciclovir are alternative medications for managing herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections.
No statements about acyclovir/famciclovir being alternatives for HSV/VZV management are included in the supplied label excerpt.
Acyclovir and famciclovir work similarly by inhibiting viral DNA replication.
No statements supporting this mechanism comparison for acyclovir/famciclovir are included in the supplied label excerpt.
Contradictions
Low
AI Statement
For recurrent episodes of genital herpes in immunocompetent adults, a common prescription of valacyclovir is 1 g taken once daily for five days.
Label Reference
Dosage and Administration (2.4), Table 1 (Genital herpes: recurrent episode and suppressive therapy regimens for immunocompetent patients).
Important Omissions
Any mention of label contraindications (hypersensitivity to valacyclovir/acyclovir or formulation components), severe cutaneous adverse reactions warning language, and other key safety sections.
Importance:
Moderate
Label-required renal impairment dosing adjustments and dialysis timing (Table 1 and hemodialysis/peritoneal dialysis guidance) in the context of dosage claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Dosing claims include at least one likely mismatch with the label excerpt for genital herpes recurrent episode (stated as 1 g once daily for five days, whereas Table 1 excerpt shows a different recurrent-episode regimen). The response also omits key contraindication and warning safety-context elements from the provided label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are absent from the supplied FDA label (especially pricing, generic availability/equivalence details, patent/website content, coupons/assistance). At least one dosing regimen for recurrent genital herpes does not match the label excerpt.
Suggested Improvement
Restrict claims to information supported by the provided label text (e.g., Table 1 renal-function–dependent dosing schedules, contraindications, and warning language). Remove or qualify all pricing/generic/insurance/patent/coupon/website statements as they are not present in the supplied prescribing information. Ensure genital herpes recurrent-episode regimens match the label excerpt exactly and distinguish recurrent episode vs suppressive therapy.